RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Gfp - if Cortex does decide to permanently stop CX-717 development for ADHD, is there any chance CX-717 would still be pushed forward in AD development (i.e. even beyond the trials that Dr. Stoll mentioned)?

In other words, might CX-717 still be viable for AD development even with the histo issue, since the AD doses will be below the threshold that triggers those cellular changes?

Or would it just be too risky to push CX-717 forward, or perhaps not cost effective since the backup compounds are being brought forward?... Aiming4.